TAS-102: 35mg/m2 given orally twice a day in a 28-day cycle, 2-week cycle of 5 days treatment followed by a 2-day rest period, and then a 14-day rest period Bevacizumab: 5mg/kg given intravenously i
Sponsors
Tokushima University Hospital, Teikyo University Chiba Medical Center
Conditions
metastatic colorectal cancer
Phase 2
TAS-102 plus Bevacizumab combination as salvage therapy in elderly patients with metastatic colorectal cancer, phase 2 trial
Active, not recruitingJPRN-UMIN000021664
Start: 2016-04-26Target: 25Updated: 2026-06-29
TAS-102 and Bevacizumab as third line chemotherapy for colorectal cancer. Phase 2 trial
RecruitingJPRN-UMIN000022438
Start: 2016-06-01Target: 31Updated: 2026-06-29
TAS-102 and Bevacizumab as second line chemotherapy for colorectal cancer. Phase 2 trial
Active, not recruitingJPRN-UMIN000022437
Start: 2016-06-01Target: 20Updated: 2026-06-29